Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms

This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475

Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research